Monographie - Cisplatin

viimane versioon :
19/11/2024

Cisplatin

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Abiplatin	Lõuna Aafrika Vabariik
Accocit	Mehhiko
Briplatin	Jaapan
Cisplatex	Brasiilia
Cisplatin	Austraalia, Austria, Belgia, Kanada, Saudi Araabia
Cisplatina	Brasiilia
Cisplatine	Belgia, Prantsusmaa
Cisplatyl	Kreeka, Prantsusmaa, Saudi Araabia, Türgi
Citoplatino	Argentiina, Itaalia
Citoplax	Brasiilia
Corsis	Mehhiko
Insel	Brasiilia
Neoplatin	Hispaania
Pamifect	India
Placis	Hispaania, Türgi
Platamine	Itaalia, Kreeka, Maroko, Tuneesia
Platanovag	Argentiina
Platiblastin	Austria
Platidiam	Poola, Ungari
Platinex	Itaalia, Saksamaa, Suurbritannia
Platinol	Ameerika ühendriigid, Austria, Belgia, Holland, Kreeka, Luksemburg, Mehhiko, Rootsi, Soome, Sveits, Taani
Platistil	Hispaania
Platistine	Belgia, Brasiilia, Luksemburg
Platosin	Belgia, Egiptus, Holland, Jaapan, Kreeka, Rumeenia, Türgi, Venetsueela
Pronto Platamine	Itaalia
Zuridry	Mehhiko

Viited : Cisplatin

	tüüp	avaldamine
3	ajaleht	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53	ajaleht	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57	ajaleht	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	ajaleht	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	ajaleht	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	ajaleht	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	ajaleht	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	ajaleht	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
147	ajaleht	Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV. Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material. Pharm World Sci 1993 ; 15: 34-36.
149	ajaleht	Rochard E, Barthes D, Courtois P. Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs. J Clin Pharm Ther 1992 ; 17: 315-318.
164	ajaleht	Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. J Clin Pharm Ther 1994 ; 19: 95-100.
169	ajaleht	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	ajaleht	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	ajaleht	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	ajaleht	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	ajaleht	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	ajaleht	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	ajaleht	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	ajaleht	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
409	ajaleht	Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987 ; 44: 124-130.
410	ajaleht	Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE. Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm 1991 ; 48: 1500-1506.
413	ajaleht	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
417	ajaleht	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
492	ajaleht	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	ajaleht	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
742	ajaleht	Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. Stability of cisplatin in aqueous solution. Am J Hosp Pharm 1979 ; 36: 38-43.
855	ajaleht	Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW. Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. Cancer Chemother Pharmacol 1992 ; 29: 252-255.
872	ajaleht	Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905	ajaleht	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	ajaleht	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080	ajaleht	La Folette JM, Arbus MH, Lauper RD. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm 1985 ; 42: 2652.
1410	ajaleht	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	ajaleht	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1729	ajaleht	Mittner A, Vincze Z, Jemnitz K. Stability of cisplatin containing infusion. Pharmazie 1998 ; 53: 490-492.
1925	ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1950	ajaleht	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1953	ajaleht	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	ajaleht	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	ajaleht	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3183	ajaleht	Sewell G Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010 ; 4, 3: 11-13.
3474	Labor	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3574	Labor	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Labor	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3602	Labor	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3670	ajaleht	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4084	Labor	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017
4137	ajaleht	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4589	Labor	Pemetrexed Mylan - Résumé des caractéristiques du produit Mylan 2021

Mentions Légales